Community | January 21, 2010 | 0 comments

Recent HIV drug trials prove new drug ineffective

Image
jubal
NEW YORK, Jan 20 (Reuters) - Merck & Co (MRK.N) on Wednesday said its experimental HIV treatment vicriviroc proved ineffective in two late-stage studies involving patients who had previously been treated with other HIV medicines.

Some industry analysts had considered the once-daily drug, which Merck acquired through its recent $41 billion purchase of Schering-Plough Corp, to be potentially the best in a new class of HIV treatments that block receptors to CCR5-- a protein that gives HIV an entry way into human immune system cells.

Wall Street had expected Merck to seek approval this year for the drug. But Merck said it now has no plans to seek marketing approval for the product "at this time."
  1. groups:
    Community,   Medicine,   HIV/AIDS Today,   HIV Alliance
  2. tags:
    News Finance HIV
  3.     
    |

0 comments // Recent HIV drug trials prove new drug ineffective

top videos